Sirolimus-Eluting Balloons Rival Drug-Eluting Stents in High Bleeding Risk Heart Patients
A prespecified substudy of 522 high bleeding risk patients finds sirolimus-eluting balloons may cut heart events and reduce antiplatelet drug burden.
Summary
For patients at high risk of bleeding who need coronary artery procedures, standard drug-eluting stents require prolonged antiplatelet drugs that raise hemorrhage risk. Sirolimus-eluting balloons (SEBs) — which deliver medication directly to the artery wall without leaving a permanent implant — offer a potential workaround. In this substudy of 522 high bleeding risk patients drawn from the larger SELUTION DeNovo randomized trial, patients treated with SEBs showed numerically lower rates of major cardiac events (4.9% vs 7.9%), major bleeding (2.3% vs 3.2%), and combined adverse events (6.8% vs 10.7%) compared to stent recipients at one year. Crucially, far more SEB patients were able to stop all antiplatelet medication safely by six months, a meaningful advantage for this vulnerable population. Though not powered for statistical significance, results suggest SEBs deserve serious consideration in this setting.
Detailed Summary
For older adults and anyone on blood thinners, the standard coronary stent creates a dilemma: the metal implant demands months or years of antiplatelet drugs to prevent clot formation, yet those same drugs raise the risk of dangerous bleeding. Finding a strategy that keeps arteries open without obligating prolonged antithrombotic therapy is a major unmet need in cardiovascular medicine — and is directly relevant to healthspan in aging populations.
The SELUTION DeNovo trial randomized 3,323 patients undergoing percutaneous coronary intervention (PCI) to either a sirolimus-eluting balloon (SEB) strategy with provisional (bailout) stenting or systematic drug-eluting stent (DES) implantation. This prespecified substudy focused on 522 patients who met Academic Research Consortium high bleeding risk (HBR) criteria — a population that is disproportionately elderly and often on oral anticoagulants.
At one year, target vessel failure (cardiac death, heart attack, or repeat revascularization) occurred in 4.9% of SEB patients versus 7.9% of DES patients — an absolute risk difference of approximately 3 percentage points favoring SEBs. Major bleeding (BARC 3–5) was 2.3% versus 3.2%, and the composite net adverse clinical events endpoint was 6.8% versus 10.7%. None of these differences reached conventional statistical significance, as the substudy was underpowered for that purpose. Notably, only 17.1% of SEB patients required bailout stenting, confirming that most could be managed without a permanent implant.
Perhaps the most clinically meaningful finding was antiplatelet medication cessation: by six months, 27.8% of SEB patients had stopped all antiplatelet therapy compared with only 14.9% of DES patients — a highly significant difference. This reflects the freedom from mandatory dual antiplatelet therapy when no stent is placed, directly reducing bleeding exposure.
While these results are hypothesis-generating rather than definitive, they make a compelling case for a prospective randomized trial powered specifically in HBR patients. For clinicians managing elderly or anticoagulated patients, SEBs represent a real and increasingly evidence-backed alternative to routine stenting. Summary is based on the abstract only.
Key Findings
- SEB strategy cut 1-year cardiac events numerically by ~3 percentage points vs. drug-eluting stents (4.9% vs. 7.9%).
- Major bleeding was lower with SEBs (2.3% vs. 3.2%), though not statistically significant.
- By 6 months, nearly twice as many SEB patients stopped all antiplatelet therapy (27.8% vs. 14.9%, p<0.001).
- Only 17.1% of SEB patients required bailout stenting, confirming most arteries can be treated without permanent implants.
- Net adverse clinical events (cardiac events plus major bleeding) were 6.8% vs. 10.7% favoring the SEB strategy.
Methodology
Prespecified substudy of the SELUTION DeNovo randomized controlled trial (n=3,323), isolating 522 patients meeting Academic Research Consortium high bleeding risk criteria (269 SEB, 253 DES). Primary endpoints were target vessel failure, BARC 3–5 bleeding, and net adverse clinical events at one year. Antithrombotic therapy was assigned per local guidelines and practice rather than a standardized protocol.
Study Limitations
The substudy was not powered to detect statistically significant differences in clinical endpoints, so all between-group differences should be interpreted as hypothesis-generating only. Antithrombotic regimens were not standardized, introducing variability that could confound bleeding comparisons. Summary is based on the abstract only; full procedural details, lesion characteristics, and subgroup analyses are unavailable for review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: